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Summary
The helical, amphipathic surfactant protein, SP-B, is
a critical element of pulmonary surfactant and hence
is an important therapeutic molecule. However, it is
difficult to isolate from natural sources in high purity.
We have created and studied three different, nonnatu-
ral analogs of a bioactive SP-B fragment (SP-B1-25),
using oligo-N-substituted glycines (peptoids) with
simple, repetitive sequences designed to favor the
formation of amphiphilic helices. For comparison, a
peptide with a similar repetitive sequence previously
shown to be a good SP mimic was also studied, along
with SP-B1-25 itself. Surface pressure-area isotherms,
surfactant film phase morphology, and dynamic ad-
sorption behavior all indicate that the peptoids are
promising mimics of SP-B1-25. The extent of biomim-
icry appears to correlate with peptoid helicity and li-
pophilicity. These biostable oligomers could serve in
a synthetic surfactant replacement to treat respiratory
distress syndrome.
Introduction
Exogenous surfactant replacement therapy is commonly
used to treat respiratory distress syndrome (RDS) in pre-
maturely born infants lacking surfactant and has greatly
decreased the mortality rate [1]. For treatment, an ani-
mal-derived lung surfactant (LS) replacement is instilled
into the alveolar network via an intratracheal tube.
Within a few days of treatment, functional surfactant
begins to be secreted into alveolar spaces as the lungs
mature. However, while the infant continues to rely on
the exogenous material to enable breathing, critical
surfactant-associated lipids and proteins can either be
recycled via tubular myelin or cleared from the alveolus
by various mechanisms, including phagocytosis by
inflammatory cells and degradation by lytic enzymes
[2–5]. Hence, the delivery of repeated doses of an LS
replacement over the course of 3–5 days is often nec-
essary. Some drawbacks to this treatment are that ani-
mal-derived replacements are expensive and carry the
risk of viral transmission [6]. For these and other
reasons, there is currently a great deal of interest in the
development of a synthetic, biomimetic LS replace-
ment that can be used for the effective, safe, and lower-
cost treatment of RDS [7–9]. The necessary biophysical
properties for a functional surfactant replacement in-
clude the following: (1) rapid adsorption to the air/water*Correspondence: a-barron@northwestern.eduinterface, (2) the ability to reach near-zero surface ten-
sion upon film compression, and (3) the ability to re-
spread upon multiple compressions and expansions of
surface area with minimal loss of surfactant into the
subphase [10]. LS is composed of w90% lipids and
w10% surfactant proteins [5, 11–15]. The hydrophobic
surfactant proteins, SP-B and SP-C, in particular are
essential to the proper biophysical function of LS for
breathing and are thought to be involved in the organ-
ization and fluidization of the lipid film [10].
Films of the main lipid component of LS, dipalmitoyl
phosphatidylcholine (DPPC), can reach near-zero sur-
face tension upon compression in vitro; however, this
molecule is slow to adsorb to the interface and exhibits
poor respreadability [10]. With the addition of palmitoyl-
oleoyl phosphatidylglycerol (POPG) and/or palmitic
acid (PA), there is an increased rate of surfactant ad-
sorption and better respreadability than with DPPC
alone [16]. However, these lipid mixtures do not reach
sufficiently low surface tensions [16]. The addition of
small amounts of SP-B and/or SP-C to the lipid film
has been shown to greatly accelerate the kinetics of
adsorption, decrease the surface tension upon com-
pression to nearly zero, and induce good respreadabil-
ity [1, 10, 17, 18]. However, due to relative scarcity, as
well as the hydrophobic and surface-active nature of
these proteins, it is difficult and costly to isolate them
from natural sources in high purity [19]. Here, we report
the development of novel, nonnatural, peptidomimetic
replacements for SP-B.
SP-B is a 79 amino acid amphipathic protein with a
predominantly helical structure [20–22]. It contains
seven cysteine residues that form three intramolecular
disulfide bonds and, in its natural form, is homodimer-
ized through an additional, intermolecular disulfide
bond [23]. Although the specific mechanisms by which
SP-B interacts with the lipid film to enable breathing
are not yet well understood, some interesting hypothe-
ses have been put forward [24]. Recently, there has been
interest in the creation of synthetic mimics of SP-B that
can serve as effective additives to a biomimetic LS re-
placement. Chemically synthesizing the entire, dimer-
ized SP-B protein is a daunting task, so small frag-
ments of the SP-B monomer have been investigated for
their ability to mimic the surface activity of the natural
protein [25–28]. A small, helical, facially amphipathic
segment from the N-terminus, SP-B1-25 (Table 1), has
been shown to retain much of the surfactant function
of the full-length synthetic peptide, both in vitro and in
vivo [26–30]. Structural studies of SP-B1-25 by FTIR [31]
and of SP-B11-25 by 2D-NMR [32] reveal that residues
8–22 are mainly helical, while residues 1–7 form a hy-
drophobic, flexible β strand, potentially for insertion
into the lipid film. These studies also show that the
α-helical domain is facially amphipathic, with cationic
and nonpolar faces [31, 32]. A simplified, de novo-
designed peptide mimic of SP-B1-25 called “KL4,” a 21-
mer, which is locally amphipathic (Table 1), composed
of only leucine and lysine, also has been investigated
for use in a synthetic LS replacement [33]. Despite its
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78Table 1. SP-B Mimic Sequences, Molar Masses, and Crude Yields
Molar Mass (Da) Crude Yield % HPLC
Oligomer Monomer Sequence (Amino to Carboxy)a Calculated: Found (%)b Elution
SP-B1-25 (C8/A, FPIPLPYAWLARALIKRIQAMIPKG 2865.55: 2865.3 56 55.9
C11/A)
KL4 KLLLLKLLLLKLLLLKLLLLK 2469.4: 2469.7 60 53.4
Peptoid 1 Nspe-Nspe-(NLys-Nspe-Nspe)5 2592.4: 2592.5 66 57.5
Peptoid 2 Nssb-Nspe-(NLys-Nssb-Nspe)5 2304.1: 2303.5 76 45.5
Peptoid 3 Nssb-Nssb-(NLys-Nssb-Nssb)5 2015.8: 2015.7 62 38.9
aCationic side chains are underlined.
bAs estimated by analytical reversed-phase HPLC of crude product. All compounds were purified to >97% homogeneity before analysis
and characterization.simplicity of sequence, the KL4 peptide, in combination a
owith lipids, has been shown to have good surface activ-
ity in vitro as well as useful in vivo efficacy for the treat- a
ament of RDS in an animal model [30, 34–38].
Since peptides have a very short half-life in vivo and a
rare relatively expensive to synthesize and purify, there
is great interest in developing nonnatural, sequence- w
sspecific oligomers as protein mimics for therapeutic
purposes [39–41]. We have been working with a family w
pof peptide mimics called “peptoids” (oligo-N-substi-
tuted glycines), which have the same backbone struc- W
ature as peptides but have their side chains appended
to the amide nitrogen rather than the α-carbon [42, 43]. e
fDiverse peptoid sequences up to w40 monomers in
length can be synthesized in good yield on a standard, T
sautomated peptide synthesizer, using a facile and
relatively low-cost “submonomer” approach [43–47]. s
mPeptoids are protease resistant due to the nonnatural
placement of the side chain [45], and although the i
sN-substituted glycine backbone is achiral, stable helical
secondary structure can be induced sterically through s
athe inclusion of chiral side chains [48, 49]. NMR struc-
tural studies of a peptoid pentamer with bulky, aro- c
matic, α-chiral side chains (i.e., with chirality introduced
at the α-carbon) revealed a polyproline type I-like heli- R
cal structure with cis-amide bonds in the backbone, a
helical pitch of w6 Å, and roughly three monomers per D
Sturn [50]. X-ray crystallographic studies later showed
that a peptoid pentamer with α-chiral aliphatic side t
fchains forms the same type of helix with a slightly
longer helical pitch (w6.7 Å) [51]. Peptoid helices in r
sboth organic and aqueous solution are stable and ro-
bust, showing no significant denaturation at temper- r
iatures of up to 75°C, even in the presence of 8 M urea
in the case of water-soluble peptoids [46]. Studies of s
fcertain heterooligomeric peptoids revealed that helices
are stabilized by the inclusion of (1) at least one-half c
tα-chiral side chains, (2) an aromatic, α-chiral face, and
(3) an aromatic, α-chiral side chain at the C terminus if i
sthe peptoid has a carboxamide tail [52]. Previous
studies have demonstrated that various sequence- e
pspecific peptoids from 3 to 22 monomers in length ex-
hibit a variety of interesting biological activities [47, t
i53, 54].
In this study, we have designed and synthesized w
cthree simple peptoid oligomers meant to mimic the
N-terminal region of SP-B. The designs for these oligo- s
Smers are based on the prominent molecular features of
SP-B , including its helicity, facial amphipathicity, t1-25nd overall lipophilicity, as well as the relative simplicity
f the KL4 sequence. The three peptoids we designed
re each 17-mers and exhibit varying extents of helicity
nd lipophilicity, as determined by CD studies in organic,
queous, and liposome environments and RP-HPLC,
espectively. The surface activities of these peptoids,
hen combined with a lipid mixture that has been
hown to mimic well the nonprotein fraction of LS [55],
as investigated and compared to that of an SP-B1-25
eptide mimic and the KL4 peptide using a Langmuir-
ilhelmy surface balance to obtain surface pressure-
rea isotherms, imaging by fluorescence microscopy to
xamine film morphology, and a pulsating bubble sur-
actometer to study surfactant adsorption dynamics.
he results reveal that these peptoids with relatively
imple sequences show good mimicry of the essential
urface-active behaviors of the SP-B1-25 peptide, with
ostly subtle but, in some cases, dramatic differences
n activity arising from their different structures. The
urface-active behaviors of these simple peptoids also
eem to correlate with their extent of helicity and over-
ll lipophilicity, with the most helical and lipophlic mole-
ule best mimicking the SP-B1-25 peptide.
esults and Discussion
esign of Mimics
P-B is known to be essential to proper respiratory func-
ion and hence must be included or replaced with a
unctional mimic in an exogenous pulmonary surfactant
eplacement for the treatment of respiratory distress
yndrome. Although it is a relatively small protein at 79
esidues, the complexity of its structure, in particular
ts multiple disulfide bonds, makes it challenging to
ynthesize chemically and then obtain in a properly
olded form. Therefore, various segments of SP-B in
ombination with surface-active lipids have been inves-
igated for their in vitro surface activity as well as their
n vivo efficacy in an animal model of RDS [25–28]. A
egment from the N terminus, SP-B1-25, has been
xtensively investigated and shows promise as a sim-
le mimic of the biophysical function of the entire pro-
ein both in vitro and in vivo [26, 27, 29, 30]. Hence, it
s this bioactive peptide that we have sought to mimic
ith a sequence-specific, folded peptoid oligomer. For
omparison with the peptoid mimics, we have synthe-
ized a 25 residue peptide based on the sequence of
P-B1-25, with cysteine-to-alanine substitutions at posi-
ions 8 and 11 to prevent the formation of unwanted
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79disulfide linkages (Table 1). This modified peptide has
previously been shown to retain the function of the orig-
inal, unmodified sequence [27]. For further comparison,
we synthesized the simple KL4 peptide that has also
previously been shown to be a good SP mimic [30, 33–
38]. After purification, the final purities of the peptides
were confirmed to be >97% by RP-HPLC, and the mo-
lar masses were confirmed to be correct at 2865 Da for
SP-B1-25 and 2470 Da for KL4 by ESI mass spec-
trometry.
Peptoid-based SP-B mimics were designed to com-
prise three main structural features of the N-terminal
protein segment that are thought to be important to its
function: (1) overall helicity, (2) overall lipophilicity, and
(3) an amphiphilic patterning of cationic and nonpolar
faces on the helix, i.e., facial amphipathicity (Figure 1).
In order to maintain a stable, helical secondary struc-
ture, we included the following sequence aspects in
two of the peptoids (1 and 2, Table 1): (1) the inclusion
of more than two-thirds α-chiral side chains, (2) the
patterning of at least one α-chiral, aromatic face on the
peptoid helix, and (3) two α-chiral side chains at the C
terminus to minimize helix fraying [52]. The third pep-
toid (3) was designed to be the most biomimetic in its
side-chain chemistry and therefore included no aro-
matic side chains, as none are found in the helical re-
gion of SP-B1-25 (Table 1). Based on the results of previ-
ous structural studies, we estimated that the proper,
most biomimetic length for the peptoids would be
about 19 monomers, assuming a helical rise of w3
monomers per turn and a pitch of w6 Å [50]. However,
since all of the peptoid mimics include one-third achiral
side chains (the lysine-like NLys monomers), we antici-
pated a slight “loosening” and lengthening of the heli-
cal structure relative to the peptoids for which the
structures were solved, so the SP-B mimics were de-
signed to be 17 monomers in length. Figure 1 shows a
schematic of the design for the peptoid mimics. In or-
der to create a cationic face on the peptoid helix, as
observed in SP-B1-25, we have placed an NLys side
chain every third monomer. The peptoid mimics each
have five cationic groups, while SP-B1-25 has four and
KL4 has five (Table 1). The nonpolar face of the helix
was made by patterning hydrophobic side chains, in-Figure 1. The Design Scheme for Amphiphilic Peptoid Helices to
Mimic SP-B1-25 and KL4
The peptoid helix is designed to have three-fold periodicity with
one cationic face (red +) and two hydrophobic faces (black).cluding N-(S)-phenylethylamine (Nspe) and/or N-(S)-
sec-butylamine (Nssb), with three-fold periodicity in the
remaining two-thirds of the peptoid sequence (side
chain structures are shown in Table 2). For peptoid 1,
the hydrophobic side chains are all α-chiral and aro-
matic (Nspe). Based on our prior studies [46, 52], we
expected this sequence patterning to produce a pep-
toid helix with excellent structural stability. We have
also designed a peptoid (2) that is somewhat more bio-
mimetic in its sequence design, including an α-chiral,
aliphatic, isoleucine-like side chain, Nssb, every third
monomer, while still maintaining one aromatic face to
help stabilize the peptoid helix [52]. Finally, we synthe-
sized a peptoid oligomer (3) with entirely aliphatic
chemistry for the hydrophobic groups, with two-thirds
Nssb monomers and a cationic NLys in every third se-
quence position. This peptoid is the closest structural
analog of the KL4 peptide.
The three peptoids were synthesized by the sub-
monomer method [43] and were obtained in good yield
(Table 1). The final purities of the compounds were con-
firmed to be >97% by RP-HPLC, and molar masses
were confirmed by ESI to correspond with the desired
molecular structures (1, 2592 Da; 2, 2304 Da; 3, 2016
Da). Due to the different side-chain chemistries em-
ployed, the lipophilicities of these molecules differed
significantly, as indicated by RP-HPLC elution times
(Table 1), with 1 > 2 > 3.
CD Spectroscopy in Water and in Liposomes
The solution conformations of these SP mimics were
studied by CD spectroscopy. Figure 2A shows a com-
parison of the CD spectra obtained for the SP-B1-25
peptide and for peptoids 1, 2, and 3 in water at room
temperature. We find that the SP-B peptide fragment
has a spectrum that is characteristic of an unstruc-
tured, random-coil conformation under these condi-
tions. However, as expected, both 1 and 2 show
α-helix-like spectral features (two minima at λw202 nm
and w218 nm and a maximum at λ w192 nm) [48, 52],
which were previously shown to correspond to a poly-
proline type I-like helical structure for peptoids com-
prising a significant fraction of Nspe side chains [48–
50, 52]. The spectrum of 1 shows more intense helical
features than that of 2, as expected due to the higher
Nspe content of 1 [52]. The CD spectrum of 3 is that
typically seen for a peptoid oligomer with a random-coil
conformation [54].
In order to characterize the conformations of these
SP-B mimics in a lipid environment similar to that of
LS, CD was also performed in an aqueous solution of
LS-mimetic liposomes, with an overall lipid concentra-
tion of 1 mM (Figure 2B). We chose a lipid formulation
that has previously been shown to be a good mimic of
the nonprotein fraction of LS, in particular DPPC:
POPG:PA 68:22:9 by weight [55]. In liposomes, all four
oligomers exhibit spectra characteristic of helices.
However, as expected, the spectrum for 3 is similar to
that typically seen for a polyproline type-I helix, with a
positive CD band at w208 nm [51]. This type of
spectrum has previously been observed for helical pep-
toids comprising chiral, aliphatic side chains [51, 52].
The spectra of the SP-B peptide, 1, and 2 all show1-25
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80Table 2. N-Substituted Glycine Side-Chain Structures
N-Substituted Glycine Oligomer or Peptoid
R = Side Chain Designator
Nspe = (S)-N-(1-phenylethyl)glycine
Nssb = (S)-N-(2-butyl)glycine
NLys = N-(4-aminobutyl)glycineα
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Figure 2. CD Spectra
CD spectra for SP-B1-25 (blue, filled circles), 1 (red, filled triangles),
t2 (green, open circles), and 3 (orange, open triangles) in water (A)
and liposomes (B). m-helix-like features typically associated with helical
eptides and peptoids of these classes. Interestingly
nd perhaps not unexpectedly, the CD spectrum of 2
ppears to be an average of that of 1 and 3 in this lipid
nvironment, most likely due to the inclusion of both
romatic and aliphatic side chains. For all compounds,
he spectra in liposomes are substantially more intense
nd are shifted toward higher wavelengths, in compari-
on to those observed in water, implying greater helicity
f all of these molecules in a lipid film. In addition, the
pectral minimum atw220 nm for both 1 and 2 is more
ntense than that at w205 nm, corresponding to more
table helical structure for peptoids [49, 52]. This
pectral feature is not observed in water, indicating that
he lipid environment induces increased helical stability
or these amphiphilic peptoids. In both aqueous and
ipophilic environments, 1 and 2 appear to be substan-
ially more helical than SP-B1-25; previous studies have
hown that peptoid helices can be formed at a shorter
ength than peptide helices due to the predominantly
teric stabilization of peptoid folding [46, 48, 49]. Sim-
lar trends for all of the peptides and peptoids studied
ere observed when CD spectra were collected in
ethanol solution (data not shown). Previous CD
tudies of KL4 have shown that it is α helical in a lipid
ilm [56].
angmuir-Wilhelmy Surface Balance Studies
angmuir-Wilhelmy surface balance (LWSB)-derived
urface pressure (Π)-area (A) isotherms for good LS re-
lacements are expected to exhibit an early lift-off (i.e.,
n increase in surface pressure at a relatively large area
er molecule [>100 mN/m], indicating rapid surfactant
dsorption to the air-water interface), a high film col-
apse pressure (near 70 mN/m, a value that corres-
onds to near-zero surface tension), and a kink or pla-
eau in the isotherm at a surface pressure of w40-50
N/m (corresponding to a phase transition in the lipid
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81film, and/or to the “squeeze-out” of molecules other
than DPPC from the monolayer) [57]. We collected and
compared Π-A isotherms for the lipid mixture by itself
(DPPC:POPG:PA 68:22:9 by weight), lipids with the ad-
dition of 2.16 mol% (10 wt%) SP-B1-25, lipids with 2.16
mol% KL4, and lipids with 2.16 mol% of either peptoid
1, 2, or 3, at both 25°C and 37°C. We chose to add 10
wt% SP-B1-25 based on previous work by other groups
who have studied SP-B at this concentration in an at-
tempt to mimic the overall protein content of LS [25,
58, 59]. We show the Π-A isotherms collected at 25°C;
similar trends were observed at 37°C (see Supplemen-
tal Data). The isotherms for the lipid mixture and the
lipid/SP-B1-25 mixture are plotted in both Figures 3A
and 3B to facilitate comparisons. Isotherms for pep-
toids 1 and 2 are plotted in Figure 3A, while those for
KL and 3 are shown in Figure 3B.Figure 3. Surface Pressure-Molecular Area Isotherms Collected on
a LWSB
(A) Π-A isotherms for lipids alone (black), lipids + 2.16 mol% SP-
B1-25 (blue, filled circles), lipids + 2.16 mol% 1 (red, filled triangles),
and lipids + 2.16 mol% 2 (green, open circles) on buffer at 25°C
with a barrier speed of 30 mm/min.
(B) Π-A isotherms for lipids alone (black), lipids + 2.16 mol% SP-
B1-25 (blue, filled circles), lipids + 2.16 mol% KL4 (purple, filled
squares), and lipids + 2.16 mol% 3 (orange, open triangles) on
buffer at 25°C with a barrier speed of 30 mm/min.4Examination of Figure 3A shows that the lipid mixture
exhibits lift-off at a molecular area ofw87 Å2/molecule.
As expected, the lipid/SP-B1-25 surfactant mixture
shows a substantially earlier lift-off [25, 27] at w110
Å2/molecule and also has an incipient plateau in the
isotherm at w50 mN/m (a more dramatic plateau is
seen at 37°C). Figure 3B shows that the lipid/KL4 mix-
ture has a level of surface activity intermediate between
that of the lipid mixture and the lipid/SP-B1-25 mixture,
with lift-off at w100 Å2/molecule and an incipient pla-
teau atw45 mN/m. When either peptoid 1 or 2 is added
to the lipids, we observe isotherms that are dramati-
cally different than what is seen for lipids alone and
much more similar to what is observed for the lipid/
SP-B1-25 mixture, with lift-off at w105 mN/m and pla-
teau in the isotherm at w45 mN/m (Figure 3A). Peptoid
3, on the other hand, has a Π-A isotherm that is very
similar to that of KL4 (Figure 3B).
At this point, it behooves us to note that the funda-
mental phase behavior of LS on a Langmuir trough, as
it affects the shape of the Π-A isotherms, is not yet
deeply understood; hence, it is not known for certain
to what extent the small differences in the isotherms for
the different peptides and peptoids might affect their in
vivo efficacy as LS replacements (we intend to investi-
gate this). This being said, we do observe some inter-
esting trends, from which we believe we can infer the
likely relative bioactivities of these different SP-B mim-
ics. For both lipid/1 and lipid/2 films, there is a very
pronounced plateau in the isotherm (Figure 3A), which
is much more dramatic than that seen for either of the
peptides and more similar to that observed for natural
LS [57, 60]. We believe that this may be due to the
greater stability of the helical structures of peptoids 1
and 2 as compared to SP-B1-25. On the other hand, it
can be seen that KL4 and peptoid 3 both show a kink
in their isotherm but not a defined plateau. Peptoid 3
has all aliphatic side chains and hence a less stable
helical structure [51], which may be why it is a better
mimic of KL4 than of SP-B1-25.
It has been shown by infrared reflection-absorption
spectroscopic studies on a Langmuir trough that both
SP-B1-25 and KL4 can adopt extended β-type confor-
mations in the lipid film at increased surface pressures
[61, 62]. It is unknown whether this α-helix-to-β-sheet
transformation takes place in the natural, dimerized
SP-B protein. Due to the lack of hydrogen-bond donors
along the N-substituted glycine backbone, peptoids are
unable to form β sheets. This may allow the peptoid
oligomers to better mimic the biophysical function of
the natural protein at high surface pressures, as com-
pared to these peptide mimics.
In order to determine the respreadability of the films,
the barriers were first compressed to near collapse (as
shown in Figure 3 at A w20 Å2/molecule), then ex-
panded fully, and compressed again. By doing this, we
are able to compare the relative respreadabilities of
these surfactant formulations based on determinations
of the lift-off areas for the first and second compres-
sions. From this analysis, we found that the respread-
abilities of films containing the peptoids 1, 2, and 3
were comparable to those of the peptides and signifi-
cantly better than that of the lipids in the absence of
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these helical, amphipathic spreading agents (data not s
shown). 6
m
cFluorescence Microscopy Imaging of Surfactant
oFilm Morphology
tFluorescence microscopy (FM) imaging, in conjunction
swith the LWSB, was used to investigate the surface
sphase morphology of lipid, lipid/peptide, and lipid/pep-
ctoid films at the air-water interface. This experimental
Tapproach was previously used to study the surface-
oactive behavior of SP-B1-25 on an instrument similar to
ours [25, 58, 59, 63]. The samples were spiked with a
Texas red-conjugated lipid (1 mol%) that preferentially P
Aresides in the more expanded surface phase. Therefore,
in the FM images shown in Figure 4, the lighter regions c
tcorrespond to the more expanded phase, while the
darker regions correspond to the more condensed ip
a
l
a
Π
d
i
d
s
d
c
d
m
s
a
o
a
n
t
i
f
t
l
m
4
(
i
a
d
w
m
l
s
c
l
l
i
(Figure 4. FM Images of Surfactant Film Phase Behavior on a Lang-
muir Trough i
FM images for lipids alone ([A] and [E]), lipids + 2.16 mol% SP- (
B1-25 ([B] and [F]), lipids + 2.16 mol% 1 ([C] and [G]), and lipids + b
2.16 mol% 2 ([D] and [H]) on buffer at 37°C collected with a barrier
sspeed of 2–10 mm/min. Images shown for Π w30 mN/m ([A]–[D])
aand Πw45 mN/m ([E]–[H]). Average domain area is shown in lower
left corner. w
phase. FM images obtained at 37°C for lipids (panels A
nd E), lipid/SP-B1-25 (B and F), lipid/1 (C and G), and
ipid/2 (D and H) at surface pressures ofw30 mN/m (A–D)
nd w45 mN/m (E and F) are shown in Figure 4. At
w30 mN/m, the lipid film exhibits condensed-phase
omains that are relatively large (averaging w98 m2
n area) and rather spread out (Figure 4A). With the ad-
ition of the SP-B1-25 peptide to the lipid film at the
ame surface pressure, a significant decrease in the
omain size is observed (to w46 m2), as well as a
oexistence of small and medium condensed-phase
omains and a more closely packed domain arrange-
ent than seen for lipids alone (Figure 4B). Similar re-
ults were found for natural SP-B in a DPPC film, with
reduction in domain size and increase in the number
f domains [64]. FM images and trends similar to this
re observed when KL4 is present in the lipid film (data
ot shown). FM imaging of both lipid/1 and lipid/2 mix-
ures at w30 mN/m reveals an essentially similar coex-
stence of small- and medium-sized domains as seen
or SP-B1-25, with a packing arrangement that appears
o be intermediate between that of lipids alone and
ipid/SP-B1-25, though with more similarity of the film
orphology to the peptide-spiked film (Figures 4C and
D). The average domain sizes for 1 (w62 m2) and 2
w40 m2) at this surface pressure are much more sim-
lar to that found for SP-B1-25 (w46 m2) than for lipids
lone (w98 m2). This difference in condensed-phase
omain size and packing is also observed at 45 mN/m,
ith lipids alone exhibiting large, widely spaced do-
ains averaging w112 m2 (Figure 4E), and the
ipid/SP-B1-25 film showing both small- and medium-
ized domains, averaging w47 m2, that are more
losely packed (Figure 4F). At 45 mN/m, lipid/1 and
ipid/2 films show a coexistence of medium-sized and
arge domains, with an average size more similar to lip-
ds alone than to the domains in the lipid/SP-B1-25 film
w82 m2 for 1 andw104 m2 for 2), though with pack-
ng arrangements resembling the lipid/SP-B1-25 film
Figures 4G and 4H). Recall, however, that SP-B1-25 has
een shown to make a transformation from α helix to β
heet at high surface pressures, such as those that we
re investigating here [61, 62]. Hence, it is unknown
hether SP-B1-25-containing films exhibit phase mor-
hology similar to what would be seen for the natural
P-B dimer at this higher surface pressure. This being
aid, SP-B1-25 does show promising in vivo activity [29,
5, 66]. It may be that the ability of an SP-B mimic to
aintain a small average condensed-domain size upon
ompression, which is expected to increase the fluidity
f the surfactant film, correlates with in vivo activity. If
his is the case, these FM images may indicate that we
till have some more work to do in optimizing the de-
ign of the peptoid-based SP-B mimics, so that upon
ompression they yield smaller condensed domains.
rends for lipid/3 films were essentially similar to those
f 1 and 2 (data not shown).
ulsating Bubble Surfactometry
pulsating bubble surfactometer (PBS) was used to
haracterize and compare the dynamic surface activi-
ies of lipids alone as well as the peptides and peptoids
n a lipid film. In this technique, a small air bubble is
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83formed within the surfactant solution, and the pressure
difference across the air-water interface is measured as
a function of either time (for a static bubble) or bubble
surface area (for a pulsating bubble) [67]. Surface ten-
sion is calculated using the Laplace equation for a
sphere. Static adsorption data were collected at the
minimum bubble radius (0.4 mm) over 20 min, and dy-
namic data were collected as the bubble surface area
was pulsed at 20 cycles per minute, with a minimum
bubble radius of 0.4 mm and a maximum radius of
0.55 mm.
Static adsorption data were collected for lipids alone,
lipids/SP-B1-25, lipids/KL4, and lipids/peptoid 1, 2, or 3
over 20 min at 37°C (Figure 5A). Note that natural LS is
typically seen to attain essentially complete (quasi-
static equilibrium) adsorption to the bubble interface in
under 1 min, with an equilibrium surface tension of 20–
25 mN/m [68]. The equilibrium surface tension attained
by lipids alone (after 20 min) is relatively high at w40
mN/m. With added SP-B1-25, the surface tension rapidly
decreases to w40 mN/m in only 2 min and then slowly
decreases to an equilibrium surface tension of w30
mN/m. The lipid/KL mixture adsorbs to the interfaceFigure 5. Static and Dynamic Adsorption Data Collected on a PBS
Static (A) and dynamic ([B] and [C]) adsorption data for lipids alone (black), lipids + 2.16 mol% SP-B1-25 (blue, filled circles), lipids + 2.16
mol% KL4 (purple, filled squares), lipids + 2.16 mol% 1 (red, filled triangles), lipids + 2.16 mol% 2 (green, open circles), and lipids + 2.16 mol%
3 (orange, open triangles) in buffer at 37°C with a pulsation rate of 20 cycles/min.4very rapidly and reaches a substantially lower equilib-
rium surface tension ofw20 mN/m. On the other hand,
the addition of peptoid 1, 2, or 3 to the lipids has an
effect very similar to that of SP-B1-25, with an immediate
decrease of surface tension to w40 mN/m followed by
a gradual decrease to an equilibrium surface tension of
w30 mN/m. All of the mimics facilitate greatly improved
adsorption kinetics over lipids alone, reaching equilib-
rium surface tensions ofw30 mN/m or less versusw40
mN/m for lipids alone. It is generally thought that the
ability of a biomimetic LS formulation to rapidly reach
a very low equilibrium surface tension correlates with
in vivo efficacy; hence, by this measure KL4 appears to
be very promising.
Dynamic adsorption data were collected on the PBS
for the same set of samples at 37°C and with a pulsa-
tion rate of 20 cycles/min; the resulting hysteresis loops
(interfacial area versus surface tension) are shown in
Figures 5B and 5C. Note that typical PBS results for
natural LS show a hysteresis loop with a maximum sur-
face tension ofw35 mN/m, a minimum surface tension
near zero, and very rapid adsorption to the interface
upon bubble compression, the latter manifested as a
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rwell as a large overall loop hysteresis [68]. As in Figure
v3, we have divided the data onto two separate plots for
sgreater clarity. Data loops for lipids alone and lipid/
uSP-B1-25 are plotted in both Figures 5B and 5C to facili-
ttate close comparisons. Loops for lipid/1 and lipid/2
rfilms are plotted in Figure 5B, while loops for lipid/KL4
iand lipid/3 films are plotted in Figure 5C. The data loop
qfor lipids alone exhibits a relatively small extent of hys-
ateresis, especially at high surface areas, and reaches a
erelatively high maximum surface tension of w57 mN/m
gand a minimum surface tension ofw7 mN/m. Upon the
[addition of SP-B1-25 to the lipid mixture, we observe a
significant decrease in both the maximum and mini-
omum surface tensions reached, to w42 mN/m and w4
pmN/m, respectively. The extent of loop hysteresis, how-
pever, is not much changed. The lipid/KL4 mixture exhib-
tits a hysteresis loop that is in many ways similar to that
sof SP-B1-25 but with some distinct features (Figure 5C):
ta lower minimum surface tension of w2 mN/m, a
oslightly higher maximum surface tension ofw44 mN/m,
tand a significant increase in loop hysteresis at
bmedium-to-high surface areas in comparison to both
slipids alone and the SP-B1-25-spiked film. These mini-
smum and maximum surface tensions are comparable
tto those previously found for lipid/KL4 films [36].
mWith the addition of either peptoid 1 or 2 (Figure 5B),
na minimum surface tension a bit lower than that of the
tlipid/SP-B1-25 mixture is observed (w4 mN/m); how-
Kever, the maximum surface tension is intermediate be-
Stween that observed for lipids alone and for the
flipid/SP-B1-25 mixture (w49 mN/m). Interestingly, the
pdata loops for peptoids 1 and 2 show a substantial
fincrease in hysteresis compared to the loop for
oSP-B1-25, indicating that the peptoid mimics of SP-B
Pmay actually be mimicking some features of natural LS
mbetter than the peptide segment (this may also be the
tcase for KL4). This increased loop hysteresis is particu-
blarly dramatic for peptoid 1, the most helical and lipo-
wphilic peptoid mimic (note that 1 is more helical in a
Flipid environment than the SP-B1-25 peptide segment p[Figure 2B] and has a molecular lipophilicity similar to
hSP-B1-25 [Table 1]). The hysteresis loop for the lipid/1 m
mixture is the most similar in shape to that observed
m
for natural LS [68] of all the formulations we studied
s
here. It differs from natural LS data loops primarily in a
the higher value of the maximum surface tension it ex- g
hibits (w49 mN/m versus w35 mN/m for natural LS).
Finally, the dynamic surface-active behavior of peptoid t
3, shown in Figure 5C, looks very similar to that of s
SP-B1-25 but with a slightly higher maximum surface t
tension. 1
a
Conclusions d
We have used four different in vitro techniques to char- f
acterize the surface-active properties of peptide and v
peptoid mimics of surfactant protein B in a lipid film: l
quasi-equilibrium measurement of Π-A isotherms on a m
LWSB, FM imaging of the surfactant film morphology, a
and both static-bubble adsorption kinetics measure- e
ments and dynamic adsorption hysteresis loops of sur- g
face tension versus interfacial area obtained with a c
SPBS. While these techniques are all widely used in theharacterization of natural LS and synthetic surfactant
eplacements, how the resulting data correlate with in
ivo efficacy is still under active study in the field. De-
pite this, we are confident of our ability to elucidate
seful information by comparing data obtained with
hese instruments. Rather than attempting to directly
elate the in vitro surface activities of the peptoid mim-
cs to their in vivo efficacy, which can be difficult to
uantitate, we have compared them to the surface
ctivities of two peptides that have been previously
stablished by in vivo as well as in vitro studies to be
ood mimics of SP-B (i.e., SP-B1-25 [26–30] and KL4
35–38]).
We find that the simple, amphipathic, helical peptoid
ligomers studied here are able to mimic well many as-
ects of the in vitro surface activities of these two re-
resentative SP-B mimics. PBS hysteresis loops reveal
hat the peptoids attain similar minimum surface ten-
ions as SP-B1-25 and KL4, and in fact 1 and 2 are able
o reach near-zero surface tension with a smaller extent
f film compression than the peptides (the latter is par-
icularly true of 1). On the other hand, the peptoid-
ased formulations show higher maximum surface ten-
ions by PBS than the peptides. All of the peptoids
how early lift-off and a biomimetic kink or plateau in
heir Π-A isotherms, with 1 and 2 showing substantially
ore pronounced plateaus, similar to what is seen for
atural LS, than SP-B1-25 or KL4. The behavior of pep-
oid 3 on the Langmuir trough is most similar to that of
L4, while on the PBS it behaves very similarly to
P-B1-25. FM images reveal film phase morphologies
or the peptoids that seem biomimetic at low surface
ressure but are intermediate between those observed
or lipids alone and lipid/SP-B1-25 films at higher values
f Π. However, comparisons of the Π-A isotherms and
BS hysteresis loops indicate that 1 and 2 might have
ore LS-like surface activity than SP-B1-25. Clearly, fu-
ure work needs to focus on establishing the correlation
etween these in vitro surfactant characterizations, as
ell as surface phase morphology and in vivo efficacy.
inally, we note that the relative surface activities of the
eptoid oligomers appear to be related to their overall
elicity and hydrophobic monomer content, with the
ost helical and lipophilic peptoid, 1, appearing to
imic the surface activities of natural LS best. Further
tudies of these peptoid mimics of SP-B will be aimed
t elucidating the underlying reasons for these intri-
uing structure-surface activity relationships.
Recall that natural LS contains two hydrophobic pro-
eins, SP-B and SP-C, both of which are highly con-
erved across many species [14] and are both thought
o be necessary for proper respiratory function [1, 10,
7, 18]. In this study, we have designed helical, facially
mphipathic peptoid mimics of SP-B1-25 and, through
etailed in vitro characterization, shown their potential
or use in an exogenous surfactant replacement. In pre-
iously published work, we have shown that a helical,
ongitudinally amphipathic peptoid 22-mer is able to
imic the surface-active behaviors of SP-C [47]. SP-B
nd SP-C are both helical, amphipathic proteins; how-
ver, there are several structural features that distin-
uish them from one another. In particular, SP-B is fa-
ially amphipathic and soluble in aqueous media, while
P-C is longitudinally amphipathic and organosoluble
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across species, functional mimics of both peptides will
likely be needed for the creation of a fully functional,
biomimetic LS replacement. We plan to continue with
our studies of these peptoid mimics by not only further
investigating the necessary structural features for their
optimization, but also studying formulations containing
peptoid mimics of both SP-B and SP-C.
Significance
We have created three different helical, amphipathic
peptoid oligomers that, despite their relatively simple
sequences, are able to mimic and perhaps even im-
prove upon the biophysical functioning of the SP-B1-25
peptide and KL4, which have been shown by others
to be useful as additives to a biomimetic LS replace-
ment. The peptoids were designed to have helical,
amphiphilic structures similar to SP-B1-25. Character-
ization of the surface-active behaviors of these SP-B
mimics with a variety of experimental tools reveals
that the lipid/peptoid films have properties that in
many ways are similar to those of lipid/SP-B1-25 and
lipid/KL4 films. While the correlation between the re-
sults of these types of in vitro characterizations of
biomimetic LS replacements and their in vivo efficacy
is only partially understood, careful comparison of
the surface-active behaviors of the peptoids with
known SP-B mimics is one way to determine their po-
tential for bioactivity. The interesting correlations we
have found between peptoid helical structure, lipo-
philicity, and surface activity will be studied further.
An entirely synthetic, biomimetic formulation contain-
ing helical peptoids could potentially fulfill a clinical
need for a safe, bioavailable, and inexpensive LS re-
placement for the treatment of respiratory distress
syndrome. Some of the many advantages of using
peptoids in therapeutic formulations are the ability of
peptoids to form stable helical secondary structure
and resist aggregation, their stability to protease de-
gradation, low cost, and relatively simple synthesis.
The ability of these simple, helical peptoids to mimic
the behavior of SP-B in a lipid environment indicates
that they have the potential for broad application in
therapeutic formulations that depend on surface-
active behavior and lipid/protein interactions.
Experimental Procedures
Materials
Peptide and peptoid synthesis reagents were purchased from Ap-
plied Biosystems (Foster City, CA) or Aldrich (Milwaukee, WI). Res-
ins, Fmoc-protected amino acids, and (t-Boc)2O were purchased
from NovaBiochem (San Diego, CA), and primary amines were
purchased from Aldrich. Solvents for HPLC were purchased from
Fisher Scientific (Pittsburgh, PA). DPPC and POPG were purchased
from Avanti Polar Lipids (Alabaster, AL), PA was purchased from
Aldrich, and Texas red-DHPE was purchased from Molecular
Probes (Eugene, OR). All chemicals were used without further puri-
fication.
Peptide and Peptoid Synthesis
The modified SP-B1-25 peptide and KL4 (Table 1) were synthesized
by Fmoc chemistry on solid support (preloaded Wang resin) using
an ABI 433A automated peptide synthesizer (Applied Biosystems).
Peptoids were also synthesized using the ABI 433A on Rink amideresin following a submonomer protocol [43], with Boc protection of
the NLys side chain [69]. Peptide and peptoid oligomers were
cleaved from the resin with a mixture of 95% TFA/water along with
necessary protecting group scavengers. Molecules were purified
by RP-HPLC using a linear gradient of 20%–95% solvent B in
solvent A over 50 min (solvent A is 0.1% TFA in water [v/v], and
solvent B is 0.1% TFA in acetonitrile [v/v]). Final purities of the
molecules were confirmed to be >97% by analytical RP-HPLC, and
molecular weights were confirmed by electrospray mass spec-
trometry.
Sample Preparation
DPPC, POPG, and PA were each individually dissolved to a known
concentration in a 3:1 solution of chloroform and methanol. DPPC,
POPG, and PA were combined at a ratio of 68:22:9 (by weight) to a
concentration of w2 mg/ml. This lipid formulation has previously
been shown to be a good mimic of the nonprotein fraction of LS
[55]. For CD studies in liposomes, lipids were dried under nitrogen
and suspended in 4 mM TRIS buffer by sonication at 50°C forw60
min to a final lipid concentration of 2 mM. For surface activity
studies, peptide or peptoid was added to the lipid mixture at 2.16
mol% (corresponding to 10 wt% of SP-B1-25) to a final concentra-
tion of w1 mg lipid/ml.
Circular Dichroism
CD spectroscopy studies were performed at room temperature in
water, methanol, and a liposome formulation (DPPC:POPG:PA
68:22:9 by weight). Peptide and peptoid samples were prepared
in water, methanol, or lipids (1 mM) and buffer (2 mM) to a final
concentration of w60 M. CD was performed on a Jasco J-715
instrument using a cylindrical quartz cuvette (Hellma, Plainview,
BY) with a 0.02 cm path length at room temperature. Each
spectrum represents the average of 40 accumulations.
Langmuir-Wilhelmy Surface Balance Studies
Our home-built Langmuir-Wilhelmy surface balance, based on a
previously designed system [25], consists of a Langmuir trough
fabricated from a solid piece of Teflon and epoxied to a copper
plate. Two Teflon barriers are located at opposite ends of the
trough and are controlled by a Unislide assembly (Velmex, Bloom-
field, NY) with a Silvermax motor (Quicksilver Controls, Covina, CA)
to adjust the surface area. Both barriers are spring loaded against
the trough to prevent surfactant leakage at surface tensions up to
72 mN/m. The subphase temperature is measured via a thermistor
and controlled by 12 thermoelectric couples (Marlow Industries,
Dallas, TX) that are connected in series and located between two
copper plates. Continuous surface pressure measurements are ob-
tained by a Wilhemy plate transducer controlled by a feedback loop
(R&K, Berlin, Germany). The barrier control, temperature control,
and pressure transducer are all interfaced with a computer to re-
cord experimental data.
For the experiments, the trough was filled with w300 ml buffer
(150 mM NaCl, 5 mM CaCl2, 10 mM HEPES [pH 6.9]) and heated to
either 25°C or 37°C. A heated cover plate was used to limit evapo-
ration. The sample, dissolved in a mixture of 3:1 chloroform and
methanol, was spread with a syringe at the air/liquid interface and
allowed to evaporate for 10 min. The barriers were cycled at 30
mm/min. The film was compressed to near collapse, expanded,
and then compressed again. All trough experiments were repeated
six times.
Fluorescence Microscopy
In order to obtain fluorescence microscopy images, a Nikon MM40
compact microscope stand with a 100W mercury lamp (Tokyo, Ja-
pan) was used in conjunction with the Langmuir trough. The fluo-
rescence was detected by a Dage-MTI three-chip color camera
(Dage-MTI, Michigan City, IN) in conjunction with a generation II
intensifier (Fryer, Huntley, IL). Samples were spiked with 1 mol% of
a fluorescently labeled lipid, Texas red-DHPE, for detection. Previ-
ous studies have shown that inclusion of the labeled lipid at this
concentration does not alter the surfactant film morphology [70].
Experiments were performed on a buffered subphase at 37°C with
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each sample.
1
Pulsating Bubble Surfactometry
A pulsating bubble surfactometer (General Transco, Largo, FL) was
used to obtain both static and dynamic adsorption data. Lipid,
lipid/peptide, and lipid/peptoid samples were dried from chloro-
1form/methanol using a DNA 120 speedvac (Thermo Electron, Hol-
brook, NY), forming a pellet. The pellet was suspended in buffer
(150 mM NaCl, 5 mM CaCl2, 10 mM HEPES [pH 6.9]) to 1.0 mg
1lipid/ml, with a final volume ofw70 l. Samples were mixed with a
pipette, sonicated with a Fisher Model 60 probe sonicator, and then
mixed with a pipette again to form a uniform solution. Samples
1were loaded into a sample chamber with putty placed on the capil-
lary end of the sample chamber; the putty was removed before
1experiments were performed. A similar method has previously been
shown to prevent sample leakage into the capillary [71]. All PBS
experiments were performed at 37°C. Static adsorption data were
1collected for 20 min at a bubble radius of 0.4 mm. Dynamic adsorp-
tion data were obtained at a frequency of 20 cycles/min for 20 min
following static adsorption, cycling between bubble radii of 0.4 mm
1and 0.55 mm. All PBS experiments were repeated six times.
1Supplemental Data
Supplemental Data are available at http://www.chembiol.com/
cgi/content/full/12/1/77/DC1/.
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